FDA Downplays Generic Drug Backlog But Plays Up Need For More Funding
Executive Summary
Concerns over FDA's backlog of unapproved abbreviated new drug applications are overblown, according to Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb
You may also be interested in...
FDA Will Refer Potentially Anti-Competitive Citizen Petitions To FTC
Questionable citizen petitions will be referred to the Federal Trade Commission, FDA says in a report made to House and Senate appropriations committees
FDA Faces Pricing Pressure As Generic Drug User Fee Debate Begins
Emerging discussions on the creation of a user fee program for generic drug review place FDA in the awkward position of potentially being seen as an arbiter of drug prices - at least indirectly
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011